New Gamma-Secretase Inhibitors for Alzheimer's Disease Treatment
Author Information
Author(s): Basi Guriqbal S, Hemphill Susanna, Brigham Elizabeth F, Liao Anna, Aubele Danielle L, Baker Jeanne, Barbour Robin, Bova Michael, Chen Xiao-Hua, Dappen Michael S, Eichenbaum Tovah, Goldbach Erich, Hawkinson Jon, Lawler-Herbold Rose, Hu Kang, Hui Terence, Jagodzinski Jacek J, Keim Pamela S, Kholodenko Dora, Latimer Lee H, Lee Mike, Marugg Jennifer, Mattson Matthew N, McCauley Scott, Miller James L, Motter Ruth, Mutter Linda, Neitzel Martin L, Ni Huifang, Nguyen Lan, Quinn Kevin, Ruslim Lany, Semko Christopher M, Shapiro Paul, Smith Jenifer, Soriano Ferdie, Szoke Balazs, Tanaka Kevin, Tang Pearl, Tucker John A, Ye Xiacong Michael, Yu Mei, Wu Jing, Xu Ying-zi, Garofalo Albert W, Sauer John Michael, Konradi Andrei W, Ness Daniel, Shopp George, Pleiss Michael A, Freedman Stephen B, Schenk Dale
Primary Institution: Elan Pharmaceuticals, Inc.
Hypothesis
APP substrate selective inhibitors of gamma-secretase would be preferable to non-selective inhibitors from a safety perspective for Alzheimer's disease therapy.
Conclusion
The discovery of ELN475516 demonstrates that it is possible to develop APP selective gamma-secretase inhibitors with potential for treatment for Alzheimer's disease.
Supporting Evidence
- ELN318463 and ELN475516 showed 75- to 120-fold selectivity for inhibiting Aβ production compared with Notch signaling.
- ELN475516 demonstrated a 33% reduction of brain Aβ in wild-type mice.
- No overt signs of systemic toxicity were observed at any dose tested.
- Discordant efficacy was noted between PDAPP and wild-type mice for ELN318463.
- ELN475516 was well tolerated in a seven-day toxicity study.
Takeaway
Scientists are trying to find safer medicines for Alzheimer's by creating drugs that only target a specific part of a protein involved in the disease.
Methodology
In vitro assays and in vivo studies in mouse models were used to evaluate the efficacy and selectivity of gamma-secretase inhibitors.
Potential Biases
Potential bias due to the involvement of authors from the pharmaceutical company developing the inhibitors.
Limitations
The study primarily focused on mouse models, which may not fully represent human responses.
Participant Demographics
Female FVB/N mice, aged two to three months.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website